New cocktail aims to tackle stomach cancer relapse
NCT ID NCT07669740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significantly. Researchers will also look for biomarkers to personalize future treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, ramucirumab, and paclitaxel
- What this could lead to
- If it works, this could offer a new treatment option for gastric cancer that comes back quickly after standard therapy, potentially shrinking tumors and delaying progression.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and there is no guarantee it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?